scholarly journals Process and outcomes evaluation of smartphone applications for Bipolar Disorder: A Scoping Review (Preprint)

Author(s):  
Iona Tatham ◽  
Ellisiv Clarke ◽  
Kelly Grieve ◽  
Pulkit Kaushal ◽  
Jan Smeddinck ◽  
...  
2021 ◽  
Author(s):  
Iona Tatham ◽  
Ellisiv Clarke ◽  
Kelly Grieve ◽  
Pulkit Kaushal ◽  
Jan Smeddinck ◽  
...  

BACKGROUND Mental Health Applications (MHAs) provide opportunities for accessible, immediate and innovative approaches to better understand mental health disorders especially those with high burden such as Bipolar Disorder (BD). Many MHAs have been developed but few have had their effectiveness evaluated. OBJECTIVE This systematic scoping review explores current process and outcome measures of MHAs for BD (MHA-BD) with an aim to provide a comprehensive overview of current research. This will identify best practice for evaluating MHA-BDs and provide a solid base for future studies whilst also aiding professionals on MHA selection in BD. METHODS A systematic literature search of the health science databases PsycINFO, Medline, Embase, EBSCO, Scopus and Web of Science was undertaken up to January 2021 to narratively assess how other studies had evaluated MHAs for BD. RESULTS A total of 3342 articles were identified, and 12 were included. Across all studies, 507 participants were studied, 376 with BD Type I or II. Data from 372 participants were analysed. Of the 507, the mean age of participants in 11 of the studies was 36.5 years, with 302 being females. The final study did not collect age data. The most widely employed validated outcome measure were YMRS used 8 times, HDRS-17 & HAMD were both applied three times and ASRM, QID and FAST used twice, while CISS, EQ-5D, GAD-7, IDS-C, MASS, MDI, Morisky-Green 8-item, PSS and WHOQOL-BREF were all utilised once. Subjective markers were also measured in 9 different studies, 6 of which used MONARCA. Mood and energy levels were the most commonly utilised subjective markers, being used 4 four times each. Eleven of the 12 studies discussed the various confounding factors and barrier to MHA-BD usage. CONCLUSIONS Reported low adherence rates, usability challenges and privacy concerns act as barriers to usage of MHA-BD. Moreover, as MHA evaluation is itself developing, so must guidance for clinicians in how to aid patient choices in m-Health. These obstacles could be ameliorated by incorporating co-production and co-design using participatory patient approaches during the development and evaluation stages of MHA-BD. Further, including qualitative aspects in trials that examine patient experience of both mental ill health and the MHA itself could result in a more patient-friendly, fit-for-purpose MHA-BD. CLINICALTRIAL Not applicable


2020 ◽  
Vol 3 (3) ◽  
Author(s):  
Enric Vincens Pons ◽  
Luis Salvador‐Carulla ◽  
Alfredo Calcedo‐Barba ◽  
Silvia Paz ◽  
Thomas Messer ◽  
...  

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Eunhee Kim ◽  
Andrius Baskys ◽  
Anandi V. Law ◽  
Moom R. Roosan ◽  
Yan Li ◽  
...  

AbstractAlzheimer’s Disease (AD) is one of the most prevalent neurodegenerative chronic diseases. As it progresses, patients become increasingly dependent, and their caregivers are burdened with the increasing demand for managing their care. Mobile health (mHealth) technology, such as smartphone applications, can support the need of these caregivers. This paper examines the published academic literature of mHealth applications that support the caregivers of AD patients. Following the PRISMA for scoping reviews, we searched published literature in five electronic databases between January 2014 and January 2021. Twelve articles were included in the final review. Six themes emerged based on the functionalities provided by the reviewed applications for caregivers. They are tracking, task management, monitoring, caregiver mental support, education, and caregiver communication platform. The review revealed that mHealth applications for AD patients’ caregivers are inadequate. There is an opportunity for industry, government, and academia to fill the unmet need of these caregiver.


2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Rachel Coe-O’Brien ◽  
Leonard Joseph ◽  
Raija Kuisma ◽  
Aatit Paungmali ◽  
Patraporn Sitilertpisan ◽  
...  

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 93 ◽  
Author(s):  
Jan K. Nowak ◽  
Jarosław Walkowiak

The current rapid spread of the novel coronavirus (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) calls for a rapid response from the research community. Lithium is widely used to treat bipolar disorder, but has been shown to exhibit antiviral activity. This brief review took a systematic approach to identify six in vitro studies reporting on the influence of lithium on coronaviral infections. We propose mechanistic investigation of the influence of lithium – alone and with chloroquine – on the SARS-CoV-2 infection.


2018 ◽  
Vol 49 (2) ◽  
pp. 177-189 ◽  
Author(s):  
Jessica A Hartmann ◽  
Barnaby Nelson ◽  
Aswin Ratheesh ◽  
Devi Treen ◽  
Patrick D McGorry

AbstractIdentifying young people at risk of developing serious mental illness and identifying predictors of onset of illness has been a focus of psychiatric prediction research, particularly in the field of psychosis. Work in this area has facilitated the adoption of the clinical staging model of early clinical phenotypes, ranging from at-risk mental states to chronic and severe mental illness. It has been a topic of debate if these staging models should be conceptualised as disorder-specific or transdiagnostic. In order to inform this debate and facilitate cross-diagnostic discourse, the present scoping review provides a broad overview of the body of literature of (a) longitudinal at-risk approaches and (b) identified antecedents of (homotypic) illness progression across three major mental disorders [psychosis, bipolar disorder (BD) and depression], and places these in the context of clinical staging. Stage 0 at-risk conceptualisations (i.e. familial high-risk approaches) were identified in all three disorders. However, formalised stage 1b conceptualisations (i.e. ultra-high-risk approaches) were only present in psychosis and marginally in BD. The presence of non-specific and overlapping antecedents in the three disorders may support a general staging model, at least in the early stages of severe psychotic or mood disorders.


Author(s):  
Zainab Jan ◽  
Noor AI Ansari ◽  
Osama Mousa ◽  
Alaa Abd-Alrazaq ◽  
Mowafa Househ ◽  
...  

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 93 ◽  
Author(s):  
Jan K. Nowak ◽  
Jarosław Walkowiak

The current rapid spread of the novel coronavirus (2019-nCoV) originating from Wuhan, China, calls for a rapid response from the research community. Lithium is widely used to treat bipolar disorder, but has been shown to exhibit antiviral activity. This brief review took a systematic approach to identify five in vitro studies reporting on the influence of lithium on coronaviral infections. We propose that in the case of urgent need, lithium be explored as a potential treatment or prophylaxis for the novel Wuhan coronavirus (2019-nCoV).


Sign in / Sign up

Export Citation Format

Share Document